Rocket Pharmaceuticals (Nasdaq:RCKT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RCKT 주식 개요

는 자회사와 함께 희귀하고 치명적인 질병에 대한 유전자 치료법 개발에 주력하는 후기 단계의 생명공학 회사로 운영되고 있습니다.

RCKT 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 95.3% 에서 거래

수익은 연간 52.84% 증가할 것으로 예상됩니다.

분석가들은 주가가 142.2% 상승할 것이라는 데 동의합니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Rocket Pharmaceuticals, Inc. 경쟁사

CG Oncology

NasdaqGS:CGON

US$2.0b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$2.4b

Vera Therapeutics

NasdaqGM:VERA

US$1.8b

Kymera Therapeutics

NasdaqGM:KYMR

US$1.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Rocket Pharmaceuticals
과거 주가
현재 주가	US$21.43
52주 최고치	US$32.53
52주 최저치	US$14.89
베타	1.07
11개월 변경	2.34%
3개월 변경 사항	-20.45%
1년 변경 사항	6.88%
33년 변화	-53.64%
5년 변화	54.06%
IPO 이후 변화	71.44%

최근 뉴스 및 업데이트

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Recent updates

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

주주 수익률

	RCKT	US Biotechs	US 마켓
7D	2.8%	-0.3%	0.3%
1Y	6.9%	11.0%	22.5%

수익률 대 산업: RCKT 지난 1년 동안 12.4 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: RCKT 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is RCKT's price volatile compared to industry and market?
RCKT volatility
RCKT Average Weekly Movement	6.8%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: RCKT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: RCKT 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1999	268	Gaurav Shah	www.rocketpharma.com

는 자회사와 함께 희귀하고 치명적인 질병에 대한 유전자 치료법 개발에 주력하는 후기 단계의 생명공학 회사로 운영되고 있습니다. 회사는 골수에서 혈액 세포의 생산을 감소시키거나 결함이 있는 혈액 세포의 생산을 촉진하는 유전적 결함인 판코니 빈혈, 면역 체계의 오작동을 유발하는 유전적 장애인 백혈구 부착 결핍-I, 만성 비구상 적혈구 용혈성 빈혈을 유발하는 희귀 적혈구 상염색체 열성 장애인 피루브산염 키나제 결핍증에 대한 임상 단계의 세 가지 생체 외 렌티바이러스 벡터 프로그램을 보유하고 있습니다. 또한 심부전으로 조기 사망에 이르는 다기관 리소좀 관련 질환인 다논병, 유전성 심장 질환인 플라코필린-2 부정맥성 심근증, BAG3 확장성 심근증에 대한 생체 내 아데노 관련 바이러스 프로그램을 임상 단계에 있습니다.

Rocket Pharmaceuticals, Inc. 기본 사항 요약

Rocket Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RCKT 기본 통계
시가총액	US$1.93b
수익(TTM)	-US$249.31m
수익(TTM)	n/a

0.0x

P/S 비율

-7.8x

P/E 비율

RCKT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RCKT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$249.31m
수익	-US$249.31m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.75
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

RCKT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RCKT 주식 개요

보상

위험 분석

Rocket Pharmaceuticals, Inc. 경쟁사

NasdaqGS:CGON

US$2.0b

NasdaqGS:RXRX

US$2.4b

NasdaqGM:VERA

US$1.8b

NasdaqGM:KYMR

US$1.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Recent updates

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Rocket Pharma: Poised For Growth In The Rare Disease Space

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Price target decreased to US$58.50

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance